SOHO 2025 | How AI and digital innovation are transforming transplant care

AI agents indeed are transforming care in bone marrow transplantation, but the transformation that we are currently living is a bit broader because we are having a digital transformation of medicine. Some of it just started and is not yet tangible for routine care, but at the experimental level, we see those prospects already quite substantially, and this is benefiting from a general transformation that we are testifying on the one hand in the terms of extensive data that is becoming available from new data sources like multi-omics data, especially in genomics. So, when we think back to when the first sequencing of only very few patient samples was a delicate task for government agencies and secured substantial funding, we can do those sequencing tasks now on our individual patients in several indications and have that data available in routine care. At the same time, we have now data standards that allow us, and these standards have been increasingly applied and integrated by multiple institutions, so even cross-institutional data standards, for example, the FHIR data standards, that enable us to bring such data sets also together. And also, we have on the other side technical innovation in terms of machine learning and artificial intelligence technologies. I think that everybody has testified the rapid rise of the generative AI technologies within the last three years, but always be reminded that this is only the most recent emergence in terms of applications in medicine. And another part that is probably not so often referred to is also the possibilities of monitoring, of digital monitoring. Wearable devices and handheld devices are enabling also that part. So, altogether, this is really a technologically driven transformation on the one hand, but in parallel, we have also transformation in terms of treatment. This is potentially less the case for patients with bone marrow transplantation because they have been, even in the past, being treated with very selective and innovative drugs, and the access to this specific subgroup has been often enabled independently of the transplantation program, also that is, of course, a very selective and also intensively treated program that enables very specialized care in those patients. But in addition, treatments such as the CAR T-cell treatments or gene therapies are becoming available for the specific subgroups. And those two evolutions, the one technologically driven, the other one biologically and medically driven, are enabling better outcomes for individual patients. But we need to match those patients directly also to the possibilities of treatment. And I think this is one of the major challenges. And here, AI is stepping into the game because it can match those two belongings better together, just as an overall introduction. And here at SOHO, this has also been discussed widely from different perspectives. There have been presentations on the use of wearable technologies for monitoring patients with lymphoma. There have been discussions of improved diagnostics, for example, utilizing digital pathology. And there have also been presentations on the use of data-driven technologies for genetic mutations and how to really solidify and consolidate those many information pieces that we are having here in the diagnostic process of leukemia.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.